Project Grant R41AI191979
Award Date
5/21/25
Completion Date
4/30/26
Dollars Obligated
$307K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $561,030 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Research Institute to develop a novel cell therapy for preventing and treating viral infections in immunocompromised patients following hematopoietic stem cell transplantation. The project aims to enhance the efficacy of virus-specific T cell therapies by genetically modifying the cells to be resistant to alemtuzumab, an...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $210,867 in funding to Drexel University to develop a novel cell-based therapy for generating donor-specific immune tolerance in kidney transplant recipients. The key focus is on engineering potent tolerogenic dendritic cells (toldcs) containing microparticles loaded with a synergistic combination of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $200,016 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to develop a non-viral platform for genome editing of hematopoietic stem cells to treat Artemis-deficient severe combined immunodeficiency (ART-SCID). The 5-year grant, effective May 8, 2025 through April 30, 2030, will support Dr. Matthew Kan's research to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cellergy Pharma Inc. in Wilmington, Delaware. The purpose of this 2-year award, with a start date of February 1, 2025, is to develop an innovative antibody drug that can efficiently and specifically eliminate IgE-producing B cells to treat severe allergic diseases. The research aims to determine the potency of the drug in...
This Project Grant award of $612,975 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to advance long-term allograft acceptance in organ transplantation. The key objectives are to: 1) Develop a translational model that combines T cell costimulation blockade with inhibition of monocyte allorecognition via CD47 to induce long-term graft acceptance, and 2) Investigate the mechanisms of monocyte...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $417,984 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, California. The grant, with a performance period from March 7, 2025 to February 28, 2026, supports research aimed at identifying actionable targets for the selective induction of regulatory T cell (Treg) differentiation to facilitate the development of stem cell-based therapies...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $343,744 to develop a comprehensive product development strategy for an Investigational New Drug (IND) submission. The goal is to facilitate Phase I clinical trials of a novel gene therapy approach using chimeric antigen receptor (CAR)-modified hematopoietic stem/progenitor cells to functionally cure HIV infection. The...
This federal Project Grant award, with funding of $306,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID), supports the development of a novel cellular immunotherapy product, Agent-797, for improving outcomes in hematopoietic stem cell transplantation (HSCT). The grant recipient, Mink Therapeutics Inc., a clinical-stage biopharmaceutical company, is collaborating with Professor Jenny Gumperz's laboratory at the University of Wisconsin School of Medicine and Public...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,648,086 to support research on inducing immune tolerance in kidney transplant recipients. The award, with a start date of May 13, 2025 and an end date of April 30, 2030, will fund preclinical trials in a non-human primate model to evaluate the use of CD20-targeted CAR T cell therapy for depleting B cells and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Datirium LLC, a for-profit limited liability company located in Cincinnati, Ohio. The grant supports the development of an automated computational pipeline that can process single-cell RNA and VDJ sequencing data from kidney biopsies or urine samples to identify alloreactive T cell clones responsible for transplant...